Over the years, in the course of using the drug in the phenomenon such as drug resistance, and from the strong competition in the market, prompting a pharmaceutical company, such as generic drugs, especially large pharmaceutical companies have to continuously for new and more effective drug product development, product research and development is extremely challenging. Below, drug development in 2014 and some hot direction and star drug analysis.

1 the tumor

At present, the global incidence of cancer has been on the rise, although with the improvement of effectiveness and drug treatment technique, the world cancer mortality decline year by year, but generally difficult to effect a radical cure, tumor patients need treatment to stop the spread of the tumor recurrence or all the way, therefore, reduce mortality, more prolonged treatment is needed on the presentation of the patients, it's about drugs put forward higher requirements, cause tumor diagnosis and treatment of demand. And specific to the types of cancer in 2014, research direction and the breast tumor's hottest, colorectal cancer, prostate cancer, etc.

In many western countries, breast cancer is the highest rates in women tumor diseases. In our country, is second only to ovarian cancer, breast cancer in female cancer. 2. Breast cancer is caused by ductal epithelial lesions of malignant tumor, a lot of drugs, researchers have been searching for more effective treatment of breast cancer drugs. In 2014, the biggest concern with Puma biotechnology Neratinib and Pfizer Palbociclib, etc.

Colorectal cancer has been high incidence of a disease in many developed countries and regions. Like some economic rising developing countries such as China, incidence of a disease also showed a trend of rising year by year. Years of colorectal cancer drug development has made gratifying achievements, increasing survival, quality of life has been improved significantly. And colorectal cancer drugs and treatment continues to develop, in 2014 amgen Vectibix FOLFOX for wild type of KRAS first-line treatment in patients with metastatic colorectal cancer is a highly successful case, obtained FDA approval.

Many other for cancer drug, now that was approved by the FDA Xtandi prostate cancer treatment drug, Cyramza gastric cancer drugs, blood cancer treatment drug Zydelig have achieved great success. Tumor immunotherapy drug development, meanwhile, is also the hot direction of antineoplastic drugs, especially by T cells, cell response, has made important progress. Therefore, many experts think the targeted cancer therapy drugs will be the main attack direction in the future cancer drug development.

2 diabetes

Metabolic diseases, diabetes is caused by dysfunction of insulin or insulin secretion defect and high blood sugar and metabolism disorders for a long time can hurt the patient body tissues and organs. And the base of large, high incidence, and has become a serious public health problem. Take many more diabetes drug market share has always been a "house of medicine" dream.

Is the spring of sugar disease research and development, 2014 SGLT Dapagliflozin - 2 inhibitor, Dapagliflozin/metformin compound dosage form, Tofogliflozin, pragliflozin, Luseogliflozin, Jardiance, successively in different countries so as to obtain the listed. Boehringer ingelheim Empagliflozin/linagliptin compound dosage form, Johnson &johnson Canagliflozin/metformin compound dosage form, boehringer ingelheim/lilly develop Empagliflozin has been registered. At the same time, astrazeneca Saxagliptin/dapagliflozin, Pfizer Ertugliflozin were already in phase III clinical.

From the point of the above preliminary statistics, 2014 sugar disease development is schools of thought contend, the flowers bloom.

3 autoimmune disease

Immune system can protect our body from bacteria and virus invasion, but in some cases, the body may have its own antigen immune reaction to hurt their own organization, leading to autoimmune disease, such as type 1 diabetes, multiple sclerosis, such as asthma and immunity, rheumatoid arthritis, crohn's disease, psoriasis, inflammatory diseases in this column. Over the years, there are many drugs workers has been committed to the development of drugs against these diseases, which also emerged a group of such as ruxolitinib, tofacitinib stars such as drugs.

2014, autoimmune disease hepatitis c treatment in the market is very active, besides Simeprevir, Faldaprevir star drugs, still thering is no lack of among them have to be seen as Sovaldi blockbuster drugs market. As the first full hepatitis c therapy for oral drugs, Sovaldi since approved for genotype 1, 2, 3, 4, since the treatment of adult patients with chronic hepatitis c, is now a growing market. From gilead sales report, Sovaldi is accounted for by more than half of gilead company sales. Second, while others, such as released August Achillion company ACH cocktail therapy for hepatitis c - 3102 such as the emergence of new therapies for hepatitis c treatment market focus this year.

summary

In addition to the above several direction over the years, incidence of disease of heart head blood-vessel continue to rise, and with the change of the modern people living habits, life pressure big, the increasingly younger patient groups. In 2014, the disease of heart head blood-vessel drug sales in the forefront of many disease drugs, market prospect is very considerable. In addition, the "ice bucket challenge" boom and policy support and so on, gradually frozen disease treatment and so on orphan drug research and development and has become a hot direction of drug development in 2014. Many disease treatment drug research and development boom for drug development in 2014 markets presents a thriving scene.